IMMUNOCORE HLDGS ADS/1 (6YG) — Financial Flexibility Index
IMMUNOCORE HLDGS ADS/1 (6YG) has a Financial Flexibility Index of -0.04x as of December 2025. Free cash flow of €-29.77 Million (operating CF €-32.66 Million minus capex €2.88 Million) represents 0% of total liabilities (€686.24 Million). Check 6YG capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
IMMUNOCORE HLDGS ADS/1 Financial Flexibility Index (2022–2025)
Historical Financial Flexibility Index trend for IMMUNOCORE HLDGS ADS/1 across 4 annual periods. See IMMUNOCORE HLDGS ADS/1 working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for IMMUNOCORE HLDGS ADS/1 (2022–2025)
Year-by-year free cash flow to debt coverage for IMMUNOCORE HLDGS ADS/1. For the full company profile including market capitalisation, see 6YG company net worth.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.01x | €-6.37 Million | €-10.71 Million | €686.24 Million | ▼ -119.3% |
| 2024 | 0.05x | €31.23 Million | €26.06 Million | €648.79 Million | ▲ +31.3% |
| 2023 | 0.04x | €8.37 Million | €2.94 Million | €228.16 Million | ▲ +114.7% |
| 2022 | -0.25x | €-47.01 Million | €-49.21 Million | €187.86 Million | — |